Astellas Pharma Gmbh

Keiko Hatanaka

Akira Tanaka

Yutaka Nakajima

Takayuki Inoue

Hiroshi Sasaki

Shohei Shirakami

Koichiro Mukoyoshi

Yasuyuki Higashi

Fumie Takahashi

Hisao Hamaguchi

Masataka Morita

Shigeki Kunikawa

Takashi Tojo

Takeshi Hondo

Kazuo Nakai

Hitoshi Sawada

Akira Okimoto

The invention relates to compound of the formula (I) or its salt, wherein &#x2014;R, &#x2014;R, &#x2014;R, &#x2014;R, &#x2014;R, -M-, &#x2014;X&#x2014; and &#x2014;Y&#x2550; are as defined in the description, their use of as, medicament, the process for their preparation and use for the treatment of JAK3 mediated diseases. 

Heterocyclic Janus Kinase 3 inhibitors

The present invention provides a compound of formula (I) having an excellent JAK3 inhibition activity and being useful as an active ingredient of an agent for treating and/or preventing various immune diseases including autoimmune diseases inflammatory diseases, and allergic diseases. The compound according to the present invention has an inhibition activity against JAK3 and is thus useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transmission (e.g., rejection during organ/tissue transplantation, autoimmune diseases, multiple sclerosis, rheumatoid arthritis, psoriasis, asthma, atopic dermatitis, Alzheimer's disease, and atherosclerotic disease), or diseases caused by abnormal cytokine signal transmission (e.g., cancer and leukemia). 

Heterocyclic janus kinase 3 inhibitors

Growing community of inventors

Tokyo, Japan

Keiko Hatanaka